Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Blinded capsule Clear all
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Probiotics (L. Helveticus, B. Longum, and B. Bifidum) on Immune Function and Digestive Health

NCT01709825
View directory record Official record
Conditions
Healthy
Interventions
Probiotic- Bifidobacterium Bifidum, Sugar Pill, Probiotic- Lactobacillus helveticus, Probiotic- Bifidobacterium longum ss. Infantis R0033
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
583 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 1 Interventional

Pilot Study of Varenicline to Treat Opioid Dependence

NCT01436474
View directory record Official record
Conditions
Chronic Pain, Opioid Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Early Phase 1 Interventional Results available

Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating Disorder

NCT00606411
View directory record Official record
Conditions
Sleep-Related Eating Disorder
Interventions
Topiramate or Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 2 Interventional

A Clinical Trial of STP0404 in Adults With HIV-1 Infection

NCT05869643
View directory record Official record
Conditions
HIV-1-infection
Interventions
Low-dose STP0404 (Pirmitegravir), Medium-dose STP0404 (Pirmitegravir), High-dose STP0404 (Pirmitegravir), Placebo
Drug
Lead sponsor
ST Pharm Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Los Angeles, California • Ft. Pierce, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

NCT02836496
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Sep 23, 2026, 8:56 PM EDT
Recruiting Phase 3 Interventional

Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)

NCT05174052
View directory record Official record
Conditions
Diabetes Mellitus, Atrial Fibrillation
Interventions
Dapagliflozin 10Mg Tab, Placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 23, 2026, 8:56 PM EDT
Terminated Phase 2 Interventional

Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)

NCT00832507
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Cicletanine, Cicletanine Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 70 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
39
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Sep 23, 2026, 8:56 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo

NCT05949008
View directory record Official record
Conditions
NIDDM, Obesity
Interventions
Metformin Extended Release (ER) Oral Tablet, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 2 Interventional

A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects

NCT00537420
View directory record Official record
Conditions
Obesity
Interventions
Nasal Placebo, Placebo Capsule, PYY3-36, Sibutramine
Drug
Lead sponsor
Nastech Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2008 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dopaminergic Dysfunction in Late-Life Depression

NCT04469959
View directory record Official record
Conditions
Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant, Levodopa, Gait Impairment
Interventions
L-Dopa, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT00851890
View directory record Official record
Conditions
Chronic Hepatitis C Virus Infection
Interventions
ABT-333, Placebo for ABT-333, Pegylated interferon, Ribavirin
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
7
States / cities
Anaheim, California • Los Angeles, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 2 Interventional Results available

Dexamethasone Dyspnea Study

NCT01670097
View directory record Official record
Conditions
Advanced Cancers, Hematologic Disorder, Solid Tumors
Interventions
Dexamethasone, Placebo, Questionnaires, Spirometer, Phone Calls
Drug · Behavioral · Device + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 2 Interventional Results available

Low Dose Naltrexone for Chronic Pain From Arthritis

NCT03008590
View directory record Official record
Conditions
Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Psoriatic
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Alpha Lipoic Acid in Geographic Atrophy

NCT02613572
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
alpha lipoic acid, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 90 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
Iowa City, Iowa • Teaneck, New Jersey • Eugene, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Acute Grape Seed Extract Supplementation on the Heart Rate Recovery in Young Individuals

NCT07137988
View directory record Official record
Conditions
Healthy Young Men
Interventions
600 mg grape seed extract, 600 mg Starch
Dietary Supplement
Lead sponsor
California Baptist University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 3 Interventional Results available

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

NCT01632904
View directory record Official record
Conditions
Polycythemia Vera
Interventions
Ruxolitinib, Hydroxyurea (HU), HU-placebo, Ruxolitinib-placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
51
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Burbank, California + 48 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First Safety Study in Humans of a Single Dose of CPG 52364

NCT00547014
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo Comparator: Cohort 1 Placebo, 52364 3 mg, Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo, 52364 10 mg, 52364 30 mg, 52364 100 mg, 52364 1 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2009 · Synced Sep 23, 2026, 8:56 PM EDT
Not yet recruiting Phase 2 Interventional

Psilocybin Therapy for Methamphetamine Use Disorder and HIV

NCT07756736
View directory record Official record
Conditions
Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)
Interventions
Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support
Drug · Behavioral
Lead sponsor
Nicky Mehtani, MD, MPH
Other
Eligibility
25 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 23, 2026, 8:56 PM EDT
Terminated Phase 3 Interventional Results available

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

NCT04912856
View directory record Official record
Conditions
Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
Interventions
XEN496
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
1 Month to 6 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 23, 2026, 8:56 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

NCT07218575
View directory record Official record
Conditions
Cowden's Disease, Cowden's Syndrome, Lhermitte-Duclos Disease, Cerebellum Dysplastic Gangliocytoma, Bannayan Zonana Syndrome, Myhre Riley Smith Syndrome, Riley Smith Syndrome, PTEN Hamartoma Tumor Syndrome, Bannayan Riley Ruvalcaba Syndrome
Interventions
Everolimus blinded oral capsules, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Utility of Nexium in Chronic Cough and Reflux Disease

NCT00287339
View directory record Official record
Conditions
Cough, GERD
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2012 · Synced Sep 23, 2026, 8:56 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

NCT04246177
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Lenvatinib, Pembrolizumab, Oral Placebo, IV Placebo, TACE
Drug · Biological · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Phase 4 Interventional Results available

PO vs. IV Acetaminophen Given Perioperatively for 24 hr Post-op Pain Control Following Total Hip or Knee Replacement

NCT02244619
View directory record Official record
Conditions
Post-op Pain
Interventions
Oral acetaminophen, IV acetaminophen
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2017 · Synced Sep 23, 2026, 8:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Guayusa Extract on Exercise Training

NCT05820399
View directory record Official record
Conditions
Desire to Exercise, Exercise Training, Physical Exertion
Interventions
Organic Guayusa Extract, Placebo
Dietary Supplement
Lead sponsor
Nathaniel Jenkins
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Sep 23, 2026, 8:56 PM EDT